NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 12 July 2022

**Location:** NICE London Office, 2 Redman Place, London E20 1JQ and via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice-chair) Present for all items
3. Dr Peter Baker-Gulliver Present for all items
4. Richard Ballerand Present for all items
5. Dr Craig Buckley Present for all items
6. Dr Andrew Champion Present for all items
7. Dr Steve Edwards Present for all items
8. Dr Michael Holmes Present for all items
9. Sumithra Maheswaran Present for items 1-5.1.3
10. Professor G.J. Melendez-Torres Present for items 5-5.2.2
11. Hugo Pedder Present for all items
12. Dr Mohit Sharma Present for all items
13. Alan Thomas Present for all items
14. Min Ven Teo Present for items 1-4.2.2
15. Bernard Khoo Present for all items
16. Michael Chambers Present for all items
17. Professor Stephen O’Brien Present for all items

NICE staff present

Janet Robertson, Associate Director Present for items 5-5.2.2

Henry Edwards, Associate Director Present for all items 1-4.2.2

Natalie Spray, Programme Manager Present for all items

Thomas Feist, Project Manager Present for items 5-5.2.2

Jeremy Powell, Project Manager Present for items 1-4.2.2

Alexandra Filby, Heath Technology Assessment Adviser Present for items 1-4.2.2

Sharlene Ting, Heath Technology Assessment Analyst Present for items 1-4.2.2

Mary Hughes, Heath Technology Assessment Adviser Present for all items 5-5.2.2

Anne Murray-Cota, Heath Technology Assessment Analyst Present for items 5-5.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Present for items 5-5.2.2

Anna Sparshatt, Senior Medical Editor Present for items 1-4.2.2

Laura Marsden, Public Involvement Adviser, PIP Present for all items

Lyn Davies, Coordinator, MIP Present for items 1-4.1.3 and 5-5.1.3

Rosalee Mason, Coordinator, MIP Present for items 1-4.1.3

Catherine Pank, Assistant Project Manager, COT Present for all items

Gemma Smith, Coordinator, COT Present for all items

Laura Kelly, Administrator, COT Present for all items

Rumana Zaman, Administrator, TA Present for items 1-4.2.2

External assessment group representatives present

GJ Melendez-Torres, PenTAG Health Technology Assessment Present for items 1-4.1.3

Madhu Muthkumar PenTAG Health Technology Assessment Present for items 1-4.1.3

Rebecca Bresnahan, Liverpool Reviews and Implementation Group (LRIG), Present for items 5-5.2.2

James Mahon, Liverpool Reviews and Implementation Group (LRIG), Present for items 5-5.2.2

Clinical, Patient & NHS England experts present

Dr Rachel Cooney, Consultant Gastroenterologist, Clinical expert nominated by the British Society for Gastroenterology, Present for items 1-4.1.3

Dr Jimmy K Limdi, Consultant Gastroenterologist, Clinical expert nominated by the British Society for Gastroenterology, Present for items 1-4.1.3

Amy Deptford, Patient expert nominated by Crohn’s and Colitis UK Present for items 1-4.1.3

Nancy Greig, Patient expert nominated by Crohn’s and Colitits UK Present for items 1-4.1.3

Steve Williamson, Deputy Cancer Drug Fund Clinical Lead, NHS England Present for items 5-5.2.2

Dave Chuter, Patient expert, nominated by Guts UK Present for items 5-5.1.3

Observers present

Dr Radha Todd, Committee member observer, NICE Present for all items

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Jane Adam, welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee members’ apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 7 June 2022

### Appraisal of Appraisal of ozanimod for treating moderately to severely active ulcerative colitis [ID3841]

* 1. Part 1 – Open session
		1. The chair, Dr Jane Adam, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Celgene Ltd
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared direct financial interests as he participated in an advisory panel for Pfizer in an unrelated disease area and had a long term contract with Takeda to support the EU Innovative Medicines Initiative (IMI) project but this did not involve consideration of specific Takeda products. It was agreed that these declarations would not prevent Michael Chambers from taking part in this appraisal.
* Nominated Clinical expert, Dr Rachel Cooney declared direct financial interests as she has received speaker fees from Falk, Janssen and Galapagos, advisory board fees from Falk, Galapagos, and Takeda, and conference fees from Ferring, Falk and Takeda. It was agreed that these declarations would not prevent Dr Cooney from providing expert advice to the committee.
* Nominated Clinical expert Professor Jimmy K Limdi declared direct financial interests as he has received speaker and consultancy fees from Abbvie, Janssen, Takeda, Tillotts, Galapagos and an advisory board fee from Arena. It was agreed that these declarations would not prevent Professor Limdi from providing expert advice to the committee.
* NICE committee member observer Dr Radha Todd declared a direct financial interest as she *was* on an advisory board for Pfizer in November 2021.  Breast cancer was the topic. It was agreed that this declaration would not prevent Dr Todd from observing the committee meeting.
* No further interests were declared for this topic.
	+ 1. The Chair led a discussion of the evidence presented to the committee.. This information was presented to the committee by Dr Steve Edwards, Richard Ballerand and Dr Jane Adam.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10732>

### Appraisal of Appraisal of nivolumab with platinum and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [ID1465]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol-Myers Squibb
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared direct financial interests as he participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and helped coordinate a training programme, run by the University of Utrecht in real world evidence for Roche, but this did not involve consideration of specific Roche products. It was agreed that these declarations would not prevent Michael Chambers from taking part in this appraisal.
* NICE committee member observer, Dr Radha Todd declared a direct financial interest as she *was* on an advisory board for Pfizer in November 2021.  Breast cancer was the topic. It was agreed that this declaration would not prevent Dr Todd from observing the committee meeting.
* No further interests were declared for this topic.
	+ 1. The chair led a discussion of the consultation comments presented to the committee.This information was presented to the committee by the chair.
	1. Part 2 – Closed session (company representatives, the patient expert, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10352>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 9 August 2022 and will start promptly at 09:30am.